6- cyano- 4- (N- ethylsulfonyl- N- methylamino)- 3- hydroxy- 2,2- dimethylchromane

RN given for (trans-(+-))-isomer

Also Known As:

293B cpd; 6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane, (trans-(+))-isomer; 6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane, (trans-(-))-isomer; chromanol 293B

Networked: 12 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Washio, Ikumi: 2 articles (06/2016 - 03/2016)
2.	Miyamoto, Norimasa: 2 articles (03/2016 - 03/2014)
3.	Ojima, Atsuko: 2 articles (03/2016 - 03/2014)
4.	Taniguchi, Tomohiko: 2 articles (03/2016 - 03/2014)
5.	Bøtker, Hans Erik: 1 article (01/2020)
6.	Elkjær, Casper Carlsen: 1 article (01/2020)
7.	Hansen, Jan: 1 article (01/2020)
8.	Jespersen, Nichlas Riise: 1 article (01/2020)
9.	Johnsen, Jacob: 1 article (01/2020)
10.	Nielsen, Jan Møller: 1 article (01/2020)

Related Diseases

1.	Infarction (Infarctions) 01/01/2020 - "XE991, but not Chromanol 293B, reduced infarct size and improved hemodynamic recovery in all isolated heart groups. " 01/01/2020 - "Isolated perfused rat hearts were divided into five groups: 1) vehicle, 2) pre-, 3) post- or 4) pre- and post-ischemic administration of XE991 or 5) chromanol 293B (Kv7.1 inhibitor) followed by infarct size quantification. " 08/01/2000 - "Before and after application of chromanol 293b (10 mg/kg), activation patterns and local refractory periods (ERPs) at pacing intervals of 300, 500 and 850 ms were obtained for the surviving epicardial muscle layer of the infarct zone (IZ) and for epi-, endo-, and midmyocardial muscle layers of both the normal zone (NZ) and the border zone (BZ) separating normal and infarcted areas. "
2.	Hypertrophy 03/01/2014 - "However, cells plated at low density had the following characteristics compared with those at high density: 1) significant enlargement in size; 2) significant increase or decrease in expression of the cardiac hypertrophy-characteristic genes NPPA, ATP2A2, ANKRD1 and MYL2 in accordance with the progression of hypertrophy; 3) significant reduction in responses to the inhibitors of cardiac slow delayed-rectifier K(+) current (IKs), chromanol 293B and HMR1556, in a cell-density-dependent manner; and 4) significant reduction in the expression of the KCNQ1 and KCNJ2 genes coding the K(+) ion channels conducting each IKs and cardiac inward rectifier outward K(+) current (IK1). "
3.	Cardiomegaly (Heart Hypertrophy) 03/01/2014 - "However, cells plated at low density had the following characteristics compared with those at high density: 1) significant enlargement in size; 2) significant increase or decrease in expression of the cardiac hypertrophy-characteristic genes NPPA, ATP2A2, ANKRD1 and MYL2 in accordance with the progression of hypertrophy; 3) significant reduction in responses to the inhibitors of cardiac slow delayed-rectifier K(+) current (IKs), chromanol 293B and HMR1556, in a cell-density-dependent manner; and 4) significant reduction in the expression of the KCNQ1 and KCNJ2 genes coding the K(+) ion channels conducting each IKs and cardiac inward rectifier outward K(+) current (IK1). "
4.	Atrial Fibrillation 07/08/2005 - "Whereas loss of KCNE1 function prolongs ventricular action potentials in humans, KCNE1-/- mice displayed unexpectedly shortened atrial action potentials, and multiple potential mechanisms were identified: (1) K+ currents (total and those sensitive to the KCNQ1 blocker chromanol 293B) were significantly increased in atrial cells from KCNE1-/- mice compared with controls, and (2) when CHO cells expressing KCNQ1 and KCNE1 were pulsed very rapidly (at rates comparable to the normal mouse heart and to human atrial fibrillation), the sigmoidicity of IKs activation prevented current accumulation, whereas cells expressing KCNQ1 alone displayed marked current accumulation at these very rapid rates. " 01/01/2004 - "Selective blockers (chromanol 293B, HMR-1556, L-735,821) of the KvLQT1 plus minK channel, which carriy the slow delayed rectifier potassium current (I(Ks)), were also considered to treat arrhythmias, including atrial fibrillation (AF). "
5.	Cardiac Arrhythmias (Arrythmia) 06/01/2016 - "Arrhythmia-like waveforms were evident for all test compounds, other than chromanol 293B, that evoked FPDc prolongation in this system and are reported to induce TdP in clinical practice. " 03/01/2016 - "Chromanol 293B, a IKs blocker, also prolonged FPDc but did not induce arrhythmia-like waveforms, even at 7.4 times the FPDc10. "

Related Drugs and Biologics

1.	Ion Channels (Ion Channel)
2.	N-propionylprocainamide
3.	dofetilide (Tikosyn)
4.	Amlodipine (Norvasc)
5.	Quinidine (Chinidin)
6.	Proteins (Proteins, Gene)
7.	Potassium
8.	Calcium Channel Blockers (Blockers, Calcium Channel)
9.	HMR 1556
10.	L 735821